Lorem ipsum dolor sit amet, consectetur adipiscing elit

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Lorem ipsum

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

The unmet clinical need

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit
amet, consectetur ad
ipisicing elit, sed do
eiusmod tempor incididunt
ut labore et
dolore magna aliqua. Ut enim ad min
im veniam, quis nostrud exercitation ullamco laboris.

Latest press releases

Annexin accelerates patient recruitment – five patients treated

Annexin Pharmaceuticals AB today announces an update on patient recruitment in the ongoing Phase 2a/Proof of Concept study NEXUS, investigating the drug candidate ANXV in retinal vein occlusion (RVO) and…

Latest press releases

Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026

Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights issue of approximately SEK 20…

Latest press releases

Favourable findings in Annexin’s ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion

Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion…

Latest press releases

Annexin engages Pareto Securities as liquidity provider

Annexin Pharmaceuticals AB (publ) today announces that the company has entered into an agreement with Pareto Securities AB to act as liquidity provider for Annexin's shares, listed on Nasdaq First…